This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • Agios announces publication of Tibsovo phase III d...
News

Agios announces publication of Tibsovo phase III data in The Lancet Oncology demonstrating significant improvement in progression-free survival in previously treated IDH1-mutant cholangiocarcinoma patients.

Read time: 2 mins
Last updated:21th May 2020
Published:20th May 2020
Condition: Cholangiocarcinoma
Type: drug
Register now for full access to medthority.com